CareDX Shares Rise on Higher Q4 Sales Outlook

Dow Jones

01/13

By Amira McKee

Shares of CareDX were higher after the medical supplies company forecast higher fourth-quarter revenue and sales gains across its business segments.

The stock rose 15% to $19.65 in Monday morning trading. Shares have fallen 17% in the past year.

The Brisbane company logged preliminary figures, predicting fourth-quarter revenue of $108 million, up 25% from the same period a year ago. Analysts polled by FactSet are expecting $102.7 million.

Full-year revenue is seen at $380 million, a 14% increase year-over-year. The company had previously guided for 2025 revenue of $372 million to $376 million.

In its 2025 fiscal year, the company said it saw gains across several sales channels, including a 10% increase in testing services revenue and 19% rise in product revenue. Patient and digital solutions revenue is seen rising 31% to about $57 million.

"We had another quarter of strong testing services volume growth and record revenue across all segments of our business," said John W. Hanna, president and chief executive officer. "Our solutions selling strategy is working. In 2026, we plan to build on this commercial momentum and advance our Transplant+ innovation pipeline."

Write to Amira McKee at amira.mckee@wsj.com

(END) Dow Jones Newswires

January 12, 2026 11:19 ET (16:19 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2603442015"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2603442015\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2603442015?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-13 00:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603442015","market":"nz","top_or_hot":-1,"title":"CareDX Shares Rise on Higher Q4 Sales Outlook","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Amira McKee \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of CareDX were higher after the medical supplies company forecast higher fourth-quarter revenue and sales gains across its business segments. \n</p>\n<p>\n  The stock rose 15% to $19.65 in Monday morning trading. Shares have fallen 17% in the past year. \n</p>\n<p>\n  The Brisbane company logged preliminary figures, predicting fourth-quarter revenue of $108 million, up 25% from the same period a year ago. Analysts polled by FactSet are expecting $102.7 million. \n</p>\n<p>\n  Full-year revenue is seen at $380 million, a 14% increase year-over-year. The company had previously guided for 2025 revenue of $372 million to $376 million. \n</p>\n<p>\n  In its 2025 fiscal year, the company said it saw gains across several sales channels, including a 10% increase in testing services revenue and 19% rise in product revenue. Patient and digital solutions revenue is seen rising 31% to about $57 million. \n</p>\n<p>\n  \"We had another quarter of strong testing services volume growth and record revenue across all segments of our business,\" said John W. Hanna, president and chief executive officer. \"Our solutions selling strategy is working. In 2026, we plan to build on this commercial momentum and advance our Transplant+ innovation pipeline.\" \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Amira McKee at amira.mckee@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 12, 2026 11:19 ET (16:19 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CareDX Shares Rise on Higher Q4 Sales Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCareDX Shares Rise on Higher Q4 Sales Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-01-13 00:19</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Amira McKee \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of CareDX were higher after the medical supplies company forecast higher fourth-quarter revenue and sales gains across its business segments. \n</p>\n<p>\n  The stock rose 15% to $19.65 in Monday morning trading. Shares have fallen 17% in the past year. \n</p>\n<p>\n  The Brisbane company logged preliminary figures, predicting fourth-quarter revenue of $108 million, up 25% from the same period a year ago. Analysts polled by FactSet are expecting $102.7 million. \n</p>\n<p>\n  Full-year revenue is seen at $380 million, a 14% increase year-over-year. The company had previously guided for 2025 revenue of $372 million to $376 million. \n</p>\n<p>\n  In its 2025 fiscal year, the company said it saw gains across several sales channels, including a 10% increase in testing services revenue and 19% rise in product revenue. Patient and digital solutions revenue is seen rising 31% to about $57 million. \n</p>\n<p>\n  \"We had another quarter of strong testing services volume growth and record revenue across all segments of our business,\" said John W. Hanna, president and chief executive officer. \"Our solutions selling strategy is working. In 2026, we plan to build on this commercial momentum and advance our Transplant+ innovation pipeline.\" \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Amira McKee at amira.mckee@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 12, 2026 11:19 ET (16:19 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CDNA","symbol_name":"CareDx","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2603442015","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603442015","pubTimestamp":1768234740,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of CareDX were higher after the medical supplies company forecast higher fourth-quarter revenue and sales gains across its business segments.The stock rose 15% to $19.65 in Monday morning trading. Shares have fallen 17% in the past year.The Brisbane company logged preliminary figures, predicting fourth-quarter revenue of $108 million, up 25% from the same period a year ago. Analysts polled by FactSet are expecting $102.7 million.Full-year revenue is seen at $380 million, a 14% increase year-over-year. The company had previously guided for 2025 revenue of $372 million to $376 million.In its 2025 fiscal year, the company said it saw gains across several sales channels, including a 10% increase in testing services revenue and 19% rise in product revenue. Patient and digital solutions revenue is seen rising 31% to about $57 million.\"We had another quarter of strong testing services volume growth and record revenue across all segments of our business,\" said John W. Hanna, president a","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CDNA":"CareDx","BK4139":"生物科技"},"translate_title":"CareDX股价因第四季度销售前景上升而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CDNA":0.9},"content_text":"By Amira McKee \n\n\n \n\n\n  Shares of CareDX were higher after the medical supplies company forecast higher fourth-quarter revenue and sales gains across its business segments. \n\n\n  The stock rose 15% to $19.65 in Monday morning trading. Shares have fallen 17% in the past year. \n\n\n  The Brisbane company logged preliminary figures, predicting fourth-quarter revenue of $108 million, up 25% from the same period a year ago. Analysts polled by FactSet are expecting $102.7 million. \n\n\n  Full-year revenue is seen at $380 million, a 14% increase year-over-year. The company had previously guided for 2025 revenue of $372 million to $376 million. \n\n\n  In its 2025 fiscal year, the company said it saw gains across several sales channels, including a 10% increase in testing services revenue and 19% rise in product revenue. Patient and digital solutions revenue is seen rising 31% to about $57 million. \n\n\n  \"We had another quarter of strong testing services volume growth and record revenue across all segments of our business,\" said John W. Hanna, president and chief executive officer. \"Our solutions selling strategy is working. In 2026, we plan to build on this commercial momentum and advance our Transplant+ innovation pipeline.\" \n\n\n \n\n\n  Write to Amira McKee at amira.mckee@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 12, 2026 11:19 ET (16:19 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}